drugset / Trial / NCT00577122
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Phase 2
Completed
30 enrolled
Indiana University
Translational Breast Cancer Research Consortium · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
Timeline
- Start
- 2007-07
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Subject | Methotrexate | Small molecule | 2.5 mg | Oral |
| Subject | medroxyprogesterone acetate | Other / unclassified | 1000 mg | Oral |